[1]
Tattersall FD,Rycroft W,Francis B,Pearce D,Merchant K,MacLeod AM,Ladduwahetty T,Keown L,Swain C,Baker R,Cascieri M,Ber E,Metzger J,MacIntyre DE,Hill RG,Hargreaves RJ, Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996; [PubMed PMID: 9121615]
[2]
Di Maio M,Bria E,Banna GL,Puglisi F,Garassino MC,Lorusso D,Perrone F, Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anti-cancer drugs. 2013 Feb; [PubMed PMID: 23165435]
[3]
Chen S,Lu M,Liu D,Yang L,Yi C,Ma L,Zhang H,Liu Q,Frimurer TM,Wang MW,Schwartz TW,Stevens RC,Wu B,Wüthrich K,Zhao Q, Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography. Nature communications. 2019 Feb 7; [PubMed PMID: 30733446]
[4]
Hornby PJ, Central neurocircuitry associated with emesis. The American journal of medicine. 2001 Dec 3; [PubMed PMID: 11749934]
[6]
Becker DE, Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesthesia progress. 2010 Winter; [PubMed PMID: 21174569]
[7]
Poli-Bigelli S,Rodrigues-Pereira J,Carides AD,Julie Ma G,Eldridge K,Hipple A,Evans JK,Horgan KJ,Lawson F, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003 Jun 15; [PubMed PMID: 12784346]
[8]
Aapro M,Carides A,Rapoport BL,Schmoll HJ,Zhang L,Warr D, Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. The oncologist. 2015 Apr; [PubMed PMID: 25795636]
[9]
Chawla SP,Grunberg SM,Gralla RJ,Hesketh PJ,Rittenberg C,Elmer ME,Schmidt C,Taylor A,Carides AD,Evans JK,Horgan KJ, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003 May 1; [PubMed PMID: 12712486]
[10]
Gan TJ,Diemunsch P,Habib AS,Kovac A,Kranke P,Meyer TA,Watcha M,Chung F,Angus S,Apfel CC,Bergese SD,Candiotti KA,Chan MT,Davis PJ,Hooper VD,Lagoo-Deenadayalan S,Myles P,Nezat G,Philip BK,Tramèr MR, Consensus guidelines for the management of postoperative nausea and vomiting. Anesthesia and analgesia. 2014 Jan; [PubMed PMID: 24356162]
[11]
Apfel CC,Malhotra A,Leslie JB, The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting. Current opinion in anaesthesiology. 2008 Aug; [PubMed PMID: 18660647]
[12]
Kang HJ,Loftus S,DiCristina C,Green S,Pong A,Zwaan CM, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. Pediatric blood [PubMed PMID: 29893452]
[13]
Salman FT,DiCristina C,Chain A,Afzal AS, Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. Journal of pediatric surgery. 2019 Jul; [PubMed PMID: 30381138]
[14]
Singh PM,Borle A,Rewari V,Makkar JK,Trikha A,Sinha AC,Goudra B, Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgraduate medical journal. 2016 Feb; [PubMed PMID: 26627976]
[15]
Patel P,Leeder JS,Piquette-Miller M,Dupuis LL, Aprepitant and fosaprepitant drug interactions: a systematic review. British journal of clinical pharmacology. 2017 Oct; [PubMed PMID: 28470980]
[16]
Aapro MS,Walko CM, Aprepitant: drug-drug interactions in perspective. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Dec; [PubMed PMID: 20488873]
[17]
Bailard N,Rebello E, Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. British journal of clinical pharmacology. 2018 Mar; [PubMed PMID: 29266364]
[18]
Gupta A,Wu CL,Elkassabany N,Krug CE,Parker SD,Fleisher LA, Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?: A systematic review of randomized controlled trials. Anesthesiology. 2003 Aug; [PubMed PMID: 12883424]
[19]
Macario A,Weinger M,Truong P,Lee M, Which clinical anesthesia outcomes are both common and important to avoid? The perspective of a panel of expert anesthesiologists. Anesthesia and analgesia. 1999 May; [PubMed PMID: 10320175]
[20]
Ballatori E,Roila F, Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health and quality of life outcomes. 2003 Sep 17; [PubMed PMID: 14521717]
[21]
Ritchie MK,Ellison M,Ranganathan P,Sizemore D,Vallejo MC, Aprepitant: A Novel Medicaton in the Prevention of Postoperative Nausea and Vomiting. The West Virginia medical journal. 2016 Nov-Dec; [PubMed PMID: 29368823]